Idenix Pharmaceuticals, Inc. (Idenix) is a biopharmaceutical company engaged in the discovery and development of drugs for the treatment of human viral diseases with operations in the United States and France. The Company�s research and development focus is on the treatment of patients with hepatitis C virus (HCV). The Company�s HCV discovery program is focused on nucleotide polymerase inhibitors and NS5A inhibitors with its ultimate goal of combining its nucleotide prodrug with its NS5A inhibitor for an internally-developed pan-genotypic regimen. The Company�s lead drug candidate from its NS5A inhibitor program is samatasvir, also known as IDX719, which has demonstrated potent, pan-genotypic activity with once-daily dosing in preclinical and proof-of-concept studies. The Company developed a non-nucleoside reverse transcriptase inhibitor, or NNRTI, drug candidate, IDX899, for the treatment of human immunodeficiency virus type-1 (HIV).